COMMUNIQUÉS West-GlobeNewswire

-
Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis
07/07/2025 -
Yiviva Presents Phase 2b Results for YIV-906 in Combination with Sorafenib in Advanced Hepatocellular Carcinoma at ASCO and ESMO GI 2025
07/07/2025 -
Onco360 Has Been Selected as a National Specialty Pharmacy for Augtyro™ (repotrectinib)
07/07/2025 -
Quipt Home Medical Acquires Healthcare System Owned Medical Equipment Provider with $6.6 Million in Revenue, and Signs Preferred Provider Agreement Covering 20 Hospitals Across 4 States
07/07/2025 -
Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria
07/07/2025 -
Medicines for Poland Announces: Without pharmaceutical factories Europe will lose any war
07/07/2025 -
Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model
07/07/2025 -
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
07/07/2025 -
LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada
07/07/2025 -
Catheter Precision, Inc. Announces First Purchase Order From University Hospital in Rennes, France
07/07/2025 -
Chugai and Gero Enter into Joint Research and License Agreement to Develop Novel Therapies for Age-Related Diseases
07/07/2025 -
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
07/07/2025 -
Collegium Announces $150 Million Share Repurchase Program
07/07/2025 -
JenaValve's Trilogy™ THV System Procedures Live Broadcast at New York Valves 2025
07/07/2025 -
Inspire Medical Systems, Inc. to Report Second Quarter 2025 Financial Results on August 4, 2025
07/07/2025 -
Extendicare Announces Timing of 2025 Second Quarter Results and Conference Call
07/07/2025 -
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
07/07/2025 -
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
07/07/2025 -
Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
07/07/2025
Pages